BML-111
LXA agonist, antiinflammatory / A novel truncated analog of lipoxin A4 which retains anti-inflammatory activity.1 Inhibits LTB4-induced leukocyte chemotaxis, IC50=5 nM).1 Attenuates hemorrhagic shock-induced acute lung injury in a rat model.2 Displays hepatoprotective effects in acetaminophen-induced liver injury in mice.3 Limits inflammatory damage in the cerebral cortex and helps maintain blood brain barrier integrity in a rat model of ischemic stroke.4 Attenuates renal ischemia/reperfusion injury via activation of p38 MAPK/PPARα/HO-1 pathway.5
Biochemicals & reagents
78606-80-1
1) Lee et al. (1991), Inhibition of leukotriene B4-induced neutrophil migration by lipoxin A4: structure-function relationships; Biochem. Biophys. Res. Commun., 180 1416 2) Li et al. (2013), BML-111 attenuates hemorrhagic shock-induced acute lung injury through inhibiting activation of mitogen-activated protein kinase pathway in rats; J. Surg. Res., 183 710 3) El-Agamy et al. (2014), Protective effects of BML-111 against acetaminophen-induced acute liver injury in mice; J. Physiol. Biochem., 70 141 4) Hawkins et al. (2014), Neurovascular protection by post-ischemic intravenous injections of the lipoxin A4 receptor agonist, BML-111, in a rat model of ischemic stroke; J. Neurochem., 129 130 5) Wu et al. (2016), BML-111-Attenuates renal Ischemia/Reperfusion Injury via Peroxisome Proliferator-Activates Receptor-α-Regulated Heme Oxygenase-1; Inflammation, 39 611
-20°C
PATHWAY: Lipid signaling; MAPK; PPAR; Transcription -- RESEARCH AREA: Immunology; Neuroscience -- DISEASE AREA: Inflammation; Ischemia